Side Effects of Anti-Inflammatory Drugs IV: The Proceedings of the IVth International Meeting on Side Effects of Anti-inflammatory Drugs, held in Sheffield, UK, 7–9 August 1995 PDF
Preview Side Effects of Anti-Inflammatory Drugs IV: The Proceedings of the IVth International Meeting on Side Effects of Anti-inflammatory Drugs, held in Sheffield, UK, 7–9 August 1995
SIDE EFFECTS OF ANTI-INFLAMMATORY DRUGS IV IVth International Meeting SIDE EFFECTS OF ANTI-INFLAMMATORY DRUGSIV The Proceedings ofthe IVth International Meeting on Side Effects of Anti-in.flammatory Drugs, held in Sheffield, UK, 7-9 August 1995 Edited by K.D. RAINSFORD Division of Biomedical Sciences School of Science and Medicine Sheffield Hallam University Sheffield, UK SPRINGER SCIENCE+BUSINESS MEDIA, B.V. Library of Congress Cataloging-in-Publication Data is available. ISBN 978-94-010-6269-5 ISBN 978-94-011-5394-2 (eBook) DOI 10.1007/978-94-011-5394-2 Printed on acid-free paper AII Rights Reserved © 1997 Springer Science+Business Media Dordrecht Originally published by Kluwer Academic Publishers in 1997 Softcover reprint of the hardcover 1s t edition 1997 No part of this publication may be reproduced or utilized in any form or by any means, electronic, mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the copyright owner. CONTENTS Preface xi I. INTRODUCTION Current status of side-effects from anti-inflammatory drugs KD Rainsford 3 II. CLINICO-EPIDEMIOLOGICAL ASPECTS The placebo response: clinical efficacy and toxicity WW Buchanan and N Bellamy 11 Side-effects of non-steroidal anti-inflammatory drugs: studies from the Tayside Medicines Monitoring Unit TM MacDonald 25 Treatment decisions, side-effect liability and cost-effectiveness in osteoarthritis GE Ehrlich 31 Measuring beneficial and adverse events in osteoarthritis clinical trials N Bellamy 35 Do NSAIDs adversely affect joint pathology in osteoarthritis? FS Walker, KD Rainsford 43 Safety of non-steroidal anti-inflammatory drugs during pregnancy and lactation ME 0stensen 55 Side-effects from biologics in the therapy of rheumatic diseases JD Isaacs 67 Oral tolerance from a general perspective, and the possible role of side-effects in the gut A Mitchison, U Gimsa, J Sieper 77 Summary of Debate: Management of side-effects from anti-inflammatory drugs KD Rainsford 81 III. FUNDAMENTAL ASPECTS The concept of conditional pharmacology and toxicology MCPowanda 87 v vi Contents Inflammation, stress and environmental factors as determinants of NSAID efficacy and toxicity MW Whitehouse 97 Do you really know what your drug looks like or how it reacts? CJL Lock (deceased) 103 IV. GASTROINTESTINAL TRACT - CLINICAL ASPECTS Intestinal pathology from NSAIDs F Halter, A Gut, C Ruchti 121 A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers J Huang, RH Hunt 139 Protection from NSAID-induced gastrointestinal damage RI Russell 153 An overview of the key role of misoprostol in the prophylaxis of NSAID- associated ulcers and their complications GC Fenn 161 Clinical update of the relative safety of nabumetone in long-term clinical trials JA Lipani, M Poland 171 Global analysis of gastrointestinal safety of a new NSAID, meloxicam M Distel, C Mueller, E Bluhmki 183 V. GASTROINTESTINAL TRACT - EXPERIMENTAL Gastrointestinal adaptation, eicosanoids, and mucosal protection from NSAIDs KD Rainsford 197 New insight into NSAID-induced gastropathy RS Spangler 207 Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine) KB Glaser 211 Differential inhibition of cyclooxygenase-l (COX-I) and -2 (COX-2) by NSAIDs: Consequences on anti-inflammatory activity versus gastric and renal safety M Pairet, L Churchill, G Trummlitz, G Engelhardt 223 Polymer delivery of the mucosal protective prostaglandin misoprostol WE Perkins, SJ Tremont, PW Collins, JC Stolzenbach, GW Gullikson 233 Contents vii Nitric oxide-releasing NSAIDs, a novel class of safe and effective anti inflammatory agents P Del Soldato, I Cuzzolin, A Adami, A Conforti, F Crivellente, G Benoni 235 Mitochondrial function and modification of NSAID carboxyl moiety T Mahmud, JM Wrigglesworth, DL Scott, I Bjarnason 243 Effects of a new class of NO-releasing NSAIDs on platelets and isolated arteries P Minuz, C Lechi, S Bonapace, S Gaino, A Adami, L Cuzzolin, P Del Soldato, G Benoni 249 Al and A2 adenosine receptors mediate opposite effects on NSAID-induced gastric ulcers in the rat C Salcedo, AG Fernandez, JM Palacios 257 Role of vagal nerve in defence mechanisms against NSAIDs-induced gastrointestinal mucosal damage G Mozsik, OME Abdel-Salam, B BOdis, 0 Karadi, L Nagy, J Szolcsanyi 265 Analysis of the inhibiting actIvity of presynaptic cxradrenoceptors against NSAID-induced gastric mucosal lesions in the rat K Gyires, C Blandizzi, M del Tacca 287 VI. DERMAT OXICITY Mechanisms of adverse reactions in the skin from anti-rheumatic drugs KD Rainsford 297 Can in-vitro assays predict chemically-induced skin damage? MG Clare, HL Cormack 305 VII. NOVEL THERAPIES The use of ketorolac tromethamine oral rinse for the treatment of periodontitis in adults PF Cavanaugh Jr 317 VIII. ABSTRACTS Variability in risk of major upper gastro-intestinal complications with individual NSAIDs. Importance of drug dose and half-life; results of meta analysis. D Henry 327 Non-steroidal associated ulcer bleeding - defining the risk factors MJS Langman Variability in exposure to NSAIDs in relation to safety J Urquhart, E de Klerk 328 viii Contents Non-steroidal anti-inflammatory drugs and infertility G Nuki, G Smith, C Hall, R Roberts 329 Perioperative use of NSAID and postoperative infectious complications K-E Giercksky 330 Medico-legal issues of non-steroidal anti-inflammatory drugs (NSAIDs) WF Kean, D Buxton 330 The use of DMARDs and combination therapies RD Sturrock 333 Non-steroidal anti-inflammatory drugs and acute appendicitis: a case-control study KS Vaidya, A MacGregor, JMM Evans, AD McMahon, MM McGilchrist, G White, DG McDevitt, FE Murray, TM MacDonald . 333 Non-steroidal anti-inflammatory drugs and colitis: a record-linkage case-control study JMM Evans, AD McMahon, MM McGilchrist, G White, FE Murray, DG McDevitt, TM MacDonald 334 New exposure to NSAIDs and hospitalisation for upper gastrointestinal events JMM Evans, AD McMahon, G White, FE Murray, MM McGilchrist, DG McDevitt, TM MacDonald 335 Topical NSAIDs and upper gastrointestinal bleeding and perforation JMM Evans, AD McMahon, MM McGilchrist, G White, FE Murray, DG McDevitt, TM MacDonald 335 Non-steroidal anti-inflammatory drugs, aspirin and colo-rectal cancer JMM Evans, AD McMahon, MM McGilchrist, G White, FE Murray, DG McDevitt, TM MacDonald 336 The pattern of prescribing of community dispensed ulcer-healing drugs in Tayside AT Prach, MM McGilchrist, G White, DG McDevitt, TM MacDonald, FE Murray 337 Clinical trials of the relative safety of nabumetone in long-term clinical trials: proposed rationale for safety profile MP Poland, JA Lipani 338 Cyclooxygenase-2: a novel target for safety anti-inflammatory drugs P Isakson 339 Inhibitory action of hydrophilic polymers on gastric lesions induced by indomethacin in rats SE Harras, YI Kim, HW Jun 340 Contents ix Copper-derivatives and gastroprotection GP Velo, L Franco, E Rizzarelli 341 The P3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat A Anthony, AK Bahl, AP Dhillon, IG Oakley, CF Spraggs, MA Trevethick, RE Pounder, AJ Wakefield 343 IX. EPILOGUE The dilemma of modern medicine W. Watson Buchanan 347 Index 351 INFLAMMOPHARMACOLOGY Basic and clinical studies on inflammation and its pharmacological control Alms and Scope The journal Inffammopharmacology publishes papers on ail aspects of inflammation and its pharmacological control, emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. Inflammopharmacology covers all the major aspects of the experimentally-induced clinical pathology, its biochemistry and cell biology, as well as the clinical and experimental pharmacology and toxicology of therapeutic agents. The emphasis on comparative aspects of the actions of drugs is intended to highlight their efficacy and toxicity profiles as well as the variability in their clinical response and safety. ISSN 0925-4692 In summary the journal covers: • Experimental development of in vitro systems and in vivo animal models • Assay methodologies • Biochemical, immunological and pharmacological studies • Clinical pharmacology and therapeutics • Drug-induced side-effects - their incidence and mechanisms • Comparative drug studies and trials • Novel approaches towards the therapy of inflammatory conditions, including brief but carefully conducted reports on therapies with as yet undefined materials (e.g. natural products, immunological agents) which may be considered as giving leads or encouragement to others to further purify or define the active ingredients and explore their actions. The journal publishes peer-reviewed unsolicited papers, reviews, short commu nications, letters to the editor, drug status reports, editorials and short summaries of hypotheses, and supplements. Editor-in-Chief: KD Rainsford Subscription price, per volume (4 issues): NLG 451.00 inclusive of postage ORDER FORM Please fill in the order form and send to your regular subSCription agent or to: Kluwer Academic Publishers. PO Box 322, 3300 AH Dordrecht, The Netherlands. USA and Canada: Kluwer Academic Publishers. PO Box 358, Accord Station, Hingham. MA 02018· 0358. USA Japan: Maruzen Co. Ltd. SubSCription Department, PO Box 5050, Tokyo Inl 100·31, Japan India: Allied Publishers SubSCription Agency, 13/14 Asaf Ali Road. Deihl 110002, India KLUWER o Please enter ....... 1997 Institutional subscriptions to Inflammopharmacology ACADEMIC · Please enter ....... 1997 Private subscriptions to Inflammopharmacology PUBLISHERS · Please send me a free sample copy of Inflammopharmaco/ogy ORDERS BY INDIVIDUALS MUST BE PREPAID · Payment enclosed to the amount of . ~. OR I authorise you to charge my credit account: " Card: . . .............. Number: . Expiry date: . . . . . . .. Signature:. OR Please invoice me Name [please pnnl] . Address. PRIVATE JOURNAL SUBSCRIPTIONS SHOULD BE SENT TO THE PUBLISHERS
The list of books you might like
